Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyanocobalamin Co-60
- Development stage
- Discontinued
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Cyanocobalamin Co-60 is a radiolabeled analog of vitamin B12, in which the cobalt atom at the core of the cobalamin molecule is replaced with radioactive cobalt isotope Co^60. It was primarily used as a diagnostic agent for pernicious anemia, particularly in the Schilling test to assess vitamin B12 absorption. The compound allowed tracking of B12 uptake and metabolism due to its radioactive properties. Cyanocobalamin Co-60 has been withdrawn from the US market for unknown reasons and is no longer in clinical use[1][3][8].
- Other names
- vitamin b12 - 60cocas 13422-53-2cas13422-53-2cas-13422-53-2
02
Targets
HC (Haptocorrin)
Beyond the preview
Go deeper on Cyanocobalamin Co-60.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyanocobalamin Co-60.